Browsing: discovery

Add preferred source AI tools are rewriting the cybersecurity landscape at unprecedented speed. The total number of registered CVE vulnerabilities globally surged from 33,512 to 66,401 over the past year—a 100% increase. Microsoft patched a record 974 vulnerabilities this month alone; Oracle released 1,448 patches in July, nearly quadruple the 309 from July 2025; Google…

An ecommerce merchant might sell the exact product a generative AI shopper wants and still not appear in the platform’s recommendations.

Sumit Vishwakarma19 Sep 2026 16:27IST New Update

Lori Locke, Chief Accounting Officer at Warner Bros. Discovery Inc WBD, sold 29,115 shares of the company on 2026-09-14, according to a recent SEC Filing. Following the transaction, the insider owns 86,906 shares of the media and entertainment giant directly.

ByteDance closed a $290M funding round for Anew Labs, its newly spun-off AI drug discovery unit, at a $1.5B valuation, Reuters reports, citing two sources familiar with the matter. Moreover, the company that owns TikTok will retain 56% of the business after this round, according to the same sources. 

Add preferred source AI startup Discovery Loop is reportedly seeking a new funding round with a target valuation of approximately $50 billion. The company was founded by several prominent AI and engineering figures from Google, including veteran engineer Jeff Dean. Just last month, the company had sought to raise $1 billion at a valuation of…

The subscription retailer introduced tools that let customers view entire outfits and enable virtual try-ons, but its financial results remain under pressure.

Verisk (Nasdaq: VRSK), a leading strategic data analytics and technology partner to the global insurance industry, today announced Verisk Fraud Discovery, a fraud prevention platform that unifies fraud intelligence, advanced analytics, network analysis, digital media forensics, and case management into a single, scalable solution.

The poor reader of today’s news is bombarded by articles hyping AI or their doom and gloom opposite. This dichotomy exists even in biopharma. Grand proclamations of the technology’s ability to accelerate novel drugs to market or sift through the scientific literature to find undiscovered targets run alongside articles that rail about how artificial intelligence…

How can a bank make every client interaction feel personal while meeting the scale, speed, security, and governance expectations of financial services?